Marker Therapeutics Inc (MRKR)

[rfj1862]

The shelf was just standard operating procedure. It should not be used to come to a conclusion about the upcoming data. Either way there or plenty of other hints that are a lot more convincing as to what the data will look like.

I agree with you about almost everything except this. It would make sense to raise before data if the pancreatic cancer data is not great, especially since solid tumors has not historically been their primary target.

Also I wish you all would stop using "PC" for pancreatic cancer. That acronym is generally used for prostate cancer.